Robert Bok, MD, PhD
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
PRIMARY OBJECTIVES: I. Part 1: To Optimize the imaging sequences that maximize signal-to-noise ratio (SNR) and intra-tumoral kPL and kPG in regions of tumor vs. adjacent benign tissue as assessed by mpMRI imaging characteristics. II. Part 2A To perform HP 13C-MRI and measure the changes in tumoral kPL and kPG. III. Part 2B: To perform HP 13C-MRI and study the metabolic effects (changes in tumor kPL and kPG). IV. Part 3: To perform HP 13C-MRI at time of Biochemical Failure and measure tumoral kPL and kPG, in previously external beam radiation therapy (EBRT) treated patients. SECONDARY OBJE…
Inclusion Criteria: 1. Participants must have biopsy-proven adenocarcinoma of the prostate, as determined by medical chart review. 2. For: 1. Part 1: Participants post-radiation therapy or currently considering EBRT. 2. Part 2A: Participants currently scheduled for or considering EBRT (no neo-adjuvant therapy planned). 3. Part 2B: Participants currently scheduled for or considering EBRT and neo-adjuvant therapy is planned. The participant has biopsy-proven adenocarcinoma of the prostate with high-risk disease, defined by the presence of at least two of following criteria: a tumor st…
Given IV
External beam radiotherapy given outside of this study
Radiation therapy given outside of this study
Imaging scan
Therapy given outside of this study as part of standard of care
Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion
Arctuva estimate
Verify or correct the compensation shown for this listing.